R&D News | pharmaphorum

News

Patients switch to lower dose of Pfizer's RA pill after safe...

Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patie

News

More positive results for Pfizer/Lilly’s non-opioid pain dru...

Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP).

News

Keytruda gets okay from FDA for adjuvant melanoma

The US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who have had surgery but still show some evidence of cancer in their lymph nodes.

News

Cipla taps Wellthy for digital therapeutics expertise

Indian pharma company Cipla has made another play in the digital medicine category by taking a near-12% stake in start-up Wellthy Therapeutics.

News

Merck/Pfizer up the pressure on BMS in first-line kidney can...

The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney cancer, setting up a possible approval in June and piling more pressure on Bristol

News

Gilead NASH drug fails late stage trial

Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial.

Patients switch to lower dose of Pfizer's RA pill after safe...

More positive results for Pfizer/Lilly’s non-opioid pain dru...

Keytruda gets okay from FDA for adjuvant melanoma

Cipla taps Wellthy for digital therapeutics expertise

Merck/Pfizer up the pressure on BMS in first-line kidney can...

Gilead NASH drug fails late stage trial

UK's Levicept builds case for osteoarthritis therapy at ACR

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks